Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

3.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.9K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

19.6K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

11.0K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.0K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.8K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

EMBO molecular medicine·2026
Same author

GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer.

Clinical epigenetics·2026
Same author

Inherent variability limits clinical utility of reproducible Parkinson's transcriptomics signatures.

NPJ Parkinson's disease·2025
Same author

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy.

bioRxiv : the preprint server for biology·2025
Same author

Axonal correlates of striatal calcium transients measured by fiber photometry.

Current biology : CB·2025
Same author

GWAS meta-analysis identifies five susceptibility loci for endometrial cancer.

EBioMedicine·2025
Same journal

Human aminoacyl-tRNA synthetases as integrators of translation and cell signalling networks.

Nature reviews. Molecular cell biology·2026
Same journal

How proteins fold.

Nature reviews. Molecular cell biology·2026
Same journal

Single-cell evidence for PANoptosome complexes.

Nature reviews. Molecular cell biology·2026
Same journal

Reply to 'Single-cell evidence for PANoptosome complexes'.

Nature reviews. Molecular cell biology·2026
Same journal

Plucking cellular ribosomes with Ribo-Tweezer.

Nature reviews. Molecular cell biology·2026
Same journal

COPII meets autophagy at the ER membrane.

Nature reviews. Molecular cell biology·2026
See all related articles

Related Experiment Video

Updated: Apr 10, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.7K

EGF-ERBB signalling: towards the systems level.

Ami Citri1, Yosef Yarden

  • 1Department of Biological Regulation, the Weizmann Institute of Science, 1 Hertzl Street, Rehovot 76100, Israel.

Nature Reviews. Molecular Cell Biology
|July 11, 2006
PubMed
Summary
This summary is machine-generated.

Signalling via ERBB/HER receptors is crucial in cancer, making them drug targets. Understanding this complex network as a robust, evolvable system reveals therapeutic strategies for cancer treatment.

More Related Videos

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
09:16

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Published on: September 11, 2015

8.8K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K

Related Experiment Videos

Last Updated: Apr 10, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.7K
Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
09:16

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Published on: September 11, 2015

8.8K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K

Area of Science:

  • Oncology
  • Systems Biology
  • Molecular Biology

Background:

  • ERBB/HER receptor signaling pathways are implicated in human cancer development.
  • These pathways are already targeted by existing cancer therapeutics.
  • The complexity of ERBB/HER signaling necessitates a systems-level perspective.

Purpose of the Study:

  • To conceptualize ERBB/HER signaling as a robust, evolvable network.
  • To explore the implications of network robustness and fragility in cancer.
  • To identify potential therapeutic strategies based on systems-level understanding.

Main Methods:

  • Network analysis of ERBB/HER signaling pathways.
  • Comparative analysis with robust biological and engineered systems.
  • Identification of network motifs, modularity, and control circuits.

Main Results:

  • ERBB/HER signaling can be modeled as a bow-tie-configured, evolvable network.
  • The network exhibits characteristics of modularity and redundancy, contributing to robustness.
  • Network fragility is an inherent trade-off associated with robustness.

Conclusions:

  • A systems-level understanding of ERBB/HER signaling is essential for cancer therapy.
  • Therapeutic opportunities exist to intercept aberrant signaling by exploiting network properties.
  • Targeting network vulnerabilities may offer novel strategies against cancer.